Splanchnic Venous Thrombosis, with Spotlight on Occult Malignancies, Anticoagulation, and Bleeding

Basit Öğe Kaydı
dc.authoridBaysal, Mehmet/0000-0001-7681-4623
dc.authoridKirkizlar, Onur/0000-0001-7523-8599
dc.authorwosidBaysal, Mehmet/E-9111-2018
dc.authorwosidKirkizlar, Onur/W-9594-2018
dc.contributor.authorUmit, Elif Gulsum
dc.contributor.authorBaysal, Mehmet
dc.contributor.authorKirkizlar, Hakki Onur
dc.contributor.authorDemir, Ahmet Muzaffer
dc.date.accessioned2024-06-12T11:15:31Z
dc.date.available2024-06-12T11:15:31Z
dc.date.issued2018
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: Splanchnic venous thrombosis (SVT) conceptually embraces thrombosis in the portal, hepatic, splenic, and mesenteric venous system thrombosis. The SVT risk factors may be classified as abdominal disorders, underlying myeloproliferative neoplasms (MPN), inherited thrombophilic syndromes, and autoimmune disorders. The aim of our study is to evaluate the risk factors for SVT and their relations with the localization of involvement and anticoagulation during the acute period and relation to major bleeding. Methods: All patients with portal vein thrombosis or splenic venous thrombosis in their radiologic evaluation report were included over a 5-year period. Results: Of the 96 patients, 87 had an identifiable risk factor for SVT (90.6%). The major risk factor was cirrhosis (60 patients, 62.5%). Other risk factors included thrombophilic conditions (12 patients, 12.6%), 6 patients had the myeloproliferative disorder (6.3%), and most interestingly, 24 had occult malignancy for which SVT was the presenting factor (25%). Within the whole group, 51 patients (53.1%) received anticoagulant treatment. Within the whole group, 30 patients developed major bleeding (31.3%), and 20 of these patients did not receive anticoagulation therapy. Twenty-five of the patients with cirrhosis suffered bleeding, and 18 of them did not receive anticoagulation therapy. Conclusion: Almost all patients with SVT had an identifiable risk factor. The follow-up and further treatments should be based on this risk factor. SVT may be the presenting finding of occult malignancies and occult malignancy should be investigated in every patient with SVT. Anticoagulation during the initial acute period should not be withheld, even in patients with the chronic liver disease with a concern for major bleeding.en_US
dc.identifier.doi10.5152/EurJTher.2018.483
dc.identifier.endpage114en_US
dc.identifier.issn2564-7784
dc.identifier.issn2564-7040
dc.identifier.issue2en_US
dc.identifier.startpage112en_US
dc.identifier.trdizinid310031en_US
dc.identifier.urihttps://doi.org/10.5152/EurJTher.2018.483
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/310031
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23973
dc.identifier.volume24en_US
dc.identifier.wosWOS:000439206700009en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherAves Press Ltden_US
dc.relation.ispartofEuropean Journal Of Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSplanchnic Venous Thrombosisen_US
dc.subjectAnticoagulationen_US
dc.subjectBleedingen_US
dc.subjectMalignancyen_US
dc.subjectVein-Thrombosisen_US
dc.titleSplanchnic Venous Thrombosis, with Spotlight on Occult Malignancies, Anticoagulation, and Bleedingen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu